Fate Therapeutics Inc
FATE1.255USD
+0.014+1.21%
시장 운영 시간 （ET）시세는 15분 지연됩니다
143.83M시가총액
손실P/E TTM
자세한 내용은 Fate Therapeutics Inc 회사
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
회사 정보
종목 코드 FATE
회사 이름Fate Therapeutics Inc
상장일Oct 01, 2013
설립일2007
CEODr. Bahram Valamehr, Ph.D.
직원 수181
유형Ordinary Share
회계 연도 종료Oct 01
주소12278 Scripps Summit Drive
도시SAN DIEGO
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호92131
전화18588751803
웹사이트https://fatetherapeutics.com/
종목 코드 FATE
상장일Oct 01, 2013
설립일2007
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
617.42K
--
Dr. John D. Mendlein, J.D., Ph.D.
Dr. John D. Mendlein, J.D., Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
311.23K
--
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
80.08K
-70.04%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
67.42K
-79.23%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
11.33K
--
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
Dr. Karin Jooss, Ph.D.
Dr. Karin Jooss, Ph.D.
Independent Director
Independent Director
9.85K
--
Dr. Xu Yuan, Ph.D.
Dr. Xu Yuan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael Lee
Mr. Michael Lee
Independent Director
Independent Director
--
--
Dr. Neelufar (Neely) Mozaffarian, M.D., Ph.D.
Dr. Neelufar (Neely) Mozaffarian, M.D., Ph.D.
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
617.42K
--
Dr. John D. Mendlein, J.D., Ph.D.
Dr. John D. Mendlein, J.D., Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
311.23K
--
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
80.08K
-70.04%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
67.42K
-79.23%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
11.33K
--
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Thu, May 22
마지막 업데이트: Thu, May 22
주주
주주 유형
주주
주주
비율
Redmile Group, LLC
11.23%
ARK Investment Management LLC
9.00%
The Vanguard Group, Inc.
8.99%
BlackRock Institutional Trust Company, N.A.
7.32%
Schonfeld Strategic Advisors LLC
6.80%
Other
56.66%
주주
주주
비율
Redmile Group, LLC
11.23%
ARK Investment Management LLC
9.00%
The Vanguard Group, Inc.
8.99%
BlackRock Institutional Trust Company, N.A.
7.32%
Schonfeld Strategic Advisors LLC
6.80%
Other
56.66%
주주 유형
주주
비율
Investment Advisor/Hedge Fund
37.69%
Investment Advisor
25.65%
Hedge Fund
18.92%
Research Firm
6.44%
Venture Capital
3.35%
Individual Investor
1.74%
Private Equity
1.47%
Bank and Trust
0.36%
Pension Fund
0.23%
Other
4.15%
기관 주식 보유
마지막 업데이트: Mon, Mar 3
마지막 업데이트: Mon, Mar 3
보고 기간
기관 수
보유 주식
비율
변동
2025Q1
439
113.58M
99.11%
-25.75M
2024Q4
487
105.43M
92.56%
-50.79M
2024Q3
521
119.20M
104.73%
-42.15M
2024Q2
531
125.64M
110.45%
-29.93M
2024Q1
543
126.44M
111.19%
-6.65M
2023Q4
556
99.29M
100.70%
-34.38M
2023Q3
581
100.01M
101.45%
-44.66M
2023Q2
611
113.36M
115.11%
-33.43M
2023Q1
624
117.20M
119.39%
-6.61M
2022Q4
637
109.94M
113.01%
-9.96M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Redmile Group, LLC
12.87M
11.23%
-296.11K
-2.25%
Dec 31, 2024
The Vanguard Group, Inc.
10.33M
9.02%
-47.55K
-0.46%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
8.49M
7.41%
+477.62K
+5.96%
Dec 31, 2024
Citadel Advisors LLC
4.38M
3.82%
+100.18K
+2.34%
Dec 31, 2024
Johnson & Johnson Innovation-JJDC, Inc.
3.38M
2.95%
--
--
Dec 31, 2024
Baker Bros. Advisors LP
3.26M
2.84%
+260.63K
+8.69%
Dec 31, 2024
Dimensional Fund Advisors, L.P.
2.90M
2.53%
+279.36K
+10.67%
Dec 31, 2024
더 보기
관련 ETF
마지막 업데이트: Fri, Jun 6
마지막 업데이트: Fri, Jun 6
이름
비율
Invesco NASDAQ Future Gen 200 ETF
0.66%
WisdomTree BioRevolution Fund
0.65%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
ProShares UltraPro Russell2000
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Biotechnology ETF
0.01%
더 보기
Invesco NASDAQ Future Gen 200 ETF
비율0.66%
WisdomTree BioRevolution Fund
비율0.65%
ProShares Hedge Replication ETF
비율0.01%
iShares Russell 2000 Value ETF
비율0.01%
Global X Russell 2000 ETF
비율0.01%
ProShares Ultra Nasdaq Biotechnology
비율0.01%
ProShares UltraPro Russell2000
비율0.01%
Invesco Nasdaq Biotechnology ETF
비율0.01%
Proshares Ultra Russell 2000
비율0.01%
iShares Biotechnology ETF
비율0.01%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
